Generated by AI
Ascendis Pharma A/S is a global biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious chronic conditions. The company uses its proprietary TransCon technology platform to create medicines designed to improve treatment delivery and address unmet medical needs. Its current portfolio includes marketed products for growth hormone deficiency and chronic hypoparathyroidism, along with clinical-stage programs in endocrinology rare disease and oncology. Headquartered in Copenhagen, Denmark, Ascendis Pharma operates across Europe and the United States, combining research, development, and commercialization capabilities to support patients, physicians, and healthcare systems in specialized therapeutic areas.
WebsiteTuborg Boulevard 12
Hellerup, 2900
Denmark
The latest articles about ASND.
Ascendis rose 3% Friday and is nearing its record high, set in July. It's among 10 new to best stock lists.
Summary of Aug 31's posts. Generated by AI.
Summary of Sep 2's posts. Generated by AI.
Summary of Mar 15's posts. Generated by AI.
Summary of Feb 28's posts. Generated by AI.
Investors talking about ASND also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.